B+
Bull case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
KROS
Keros TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The investment case rests on a long cash runway, lower operating spend, a Phase 2 DMD program with initial data expected in 2027, and Takeda advancing elritercept. The packet's $19.8333 median target implies substantial upside, but the target count is unavailable and should not be treated as a robust consensus.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.9.
What can break
Post-earnings price action showed weak follow-through, while reported analyst targets were reduced after the print.
Momentum
27
Value
61
Sentiment
78
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.50 · Bull $18.00 · Bear $7.50Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $19.83
Why
Momentum27 · Δ7d +8.3
Value61 · Δ7d 0.0
Sentiment78 · Δ7d +5.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.9.
Contradictions & invalidation
- • Post-earnings price action showed weak follow-through, while reported analyst targets were reduced after the print.
- • Q2 EPS missed consensus and revenue was zero; Keros has no marketed product or recurring product revenue. [#PR-EARNINGS-2026-08-04]
- • The Q2 loss of $1.45 per share missed third-party consensus, revenue was zero, and Keros has no marketed product.
Catalyst clock
2026-08-17
Q2 earnings digestion: runway offsets operating miss
Lead driver: Sentiment · See AI snapshot
Momentum
27
9% active weight
Current posture
7d trendImproving
Δ7d
+8.3
Δ21d
+12.1
Value
61
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+17.0
Sentiment
78
62% active weight
Current posture
7d trendImproving
Δ7d
+5.9
Δ21d
-5.7
Why this grade
Composite grade B. Momentum 26.6 / Value 61.3 / Sentiment 77.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$207.79M
Beta
0.87
Shares Out
19.83M
P/E (TTM)
11.6
P/S (TTM)
2.21
P/FCF (TTM)
6.27
Rev YoY
-100.0%
EPS YoY
+91.8%
Gross Margin
+89.3%
Op Margin
-332.3%
Net Debt
-$270.53M
Current Ratio
21.96
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data